Lv11
18 积分 2022-12-09 加入
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
1小时前
待确认
[Consensus on immunotherapy for small cell lung cancer(2024 edition)]
1个月前
已完结
Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC
1个月前
已完结
EML4‐ALK fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non‐small cell lung cancer
1个月前
已完结
Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib
1个月前
已完结
表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌中国专家共识(2025版)
1个月前
已关闭
[Expert consensus on diagnosis and treatment of advanced non-small cell lung cancer with HER-2 alterations (2025 edition)]
1个月前
已完结
Mechanisms and functions of p38 MAPK signalling
1个月前
已完结
Prevalence and Clinical Implications of Mismatch Repair-Proficient Colorectal Cancer in Patients With Lynch Syndrome
1个月前
已完结
HIF-2–Dependent Regulation of PTHrP and Paraneoplastic Hypercalcemia in Aggressive Clear-Cell Renal Cell Carcinoma
2个月前
已完结
皖公网安备34019202002308
